Tandem Diabetes Care (TNDM) to Release Quarterly Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) is expected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $251.39 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $31.00 on Monday. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -16.06 and a beta of 1.32. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The company’s 50-day moving average is $35.48 and its two-hundred day moving average is $36.70. Tandem Diabetes Care has a 12-month low of $24.42 and a 12-month high of $53.69.

Wall Street Analyst Weigh In

TNDM has been the topic of several recent analyst reports. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 price objective on the stock. Canaccord Genuity Group lowered their price objective on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Barclays increased their price objective on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Citigroup decreased their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target for the company in a research report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.